Aptamer Group (LSE:APTA), the developer of synthetic binding molecules, is heading towards its full-year results with a growing revenue base, a larger sales pipeline and a funding runway it says now stretches into 2028. In a trading update published on 13 July 2026, the company said it expected revenue for the year ended 30 June 2026 to rise by about 25% to roughly £1.5 million, while its sales pipeline expanded by 55% to £4.8 million.

What Aptamer Does

Aptamer Group develops Optimer binders, which are engineered nucleic acid molecules designed to act as alternatives to antibodies. These binders can be used in research tools, diagnostics and therapeutic delivery. The company earns money through fee-for-service discovery programmes for partners in life sciences and pharmaceuticals, and is increasingly seeking licensing deals that could bring royalties if partners commercialise products using its technology. It is also building its own pipeline of development assets in areas such as targeted radiopharmaceuticals and the delivery of genetic medicines.

Latest Developments

According to the July update, revenue growth came from fee-for-service work and initial licensing income, with an order book of £0.6 million. The company highlighted delivery of Optimer binders to a global life sciences company under a commercial licence that includes a 2% royalty on future product sales, subject to successful validation. A food fortification rapid test programme was also progressing, with binders expected to be supplied to Imperial College London.

Earlier, on 25 June 2026, Aptamer gave a programme and technical update. It said an artificial intelligence model trained on an in-house dataset of 450,000 sequences across 42 protein targets had identified initial Optimer candidates for laboratory testing. Material for its radioligand therapy work had been shipped to partners ahead of in vivo studies, with results targeted by the end of 2026.

In March 2026 Aptamer launched a targeted radiopharmaceutical programme with consultancy Radiopharmium, identifying three therapeutic targets. Combined with an existing programme alongside a top-three global pharmaceutical partner, it expects its radiotherapy pipeline to reach four assets.

Financial Picture

Aptamer remains loss-making. For the year to 30 June 2025 it reported a loss before tax of £2.57 million and an adjusted EBITDA loss of £2.19 million, with cash of £1.06 million at the year end. In its interim results in March 2026, it reported first-half revenue up 27% to £0.83 million. A placing, subscription and retail offer completed in April 2026 raised £4.1 million, which the company says provides cash runway into at least 2028. No dividend is paid.

Sector and Index Context

Aptamer is one of the smaller life sciences companies on AIM and forms part of the FTSE AIM All Share Index. Early-stage biotech companies on the junior market have faced difficult funding conditions in recent years. Radiopharmaceuticals, however, remain an active area for global drug developers, and partnerships in this field can attract attention.

Key Risks

The company's revenues are still small relative to its cost base, so further losses are likely in the near term. Licensing income depends on partners successfully validating and launching products, which Aptamer does not control. Preclinical data in radiopharmaceuticals and drug delivery may not translate into successful in vivo results. Shareholders have also experienced dilution from past fundraisings, and the share price has been volatile over the past year.

What to Watch Next

The next major milestone is the audited full-year results for the year to 30 June 2026. Investors will also watch for the in vivo radioligand data targeted by the end of 2026, conversion of the £4.8 million pipeline into contracts and any further licensing agreements carrying royalties.